- National Resilience is investing $225 million into its Ohio facility. The company is also expanding its manufacturing operations in North Carolina.
National Resilience, a technology-focused biomanufacturing company, has announced a significant investment of $225 million into its Ohio facility.
By 2025, it aims to produce more than 200 million units across its network for various types of treatments, including the widely used GLP-1 treatments for diabetes and obesity.
The CDMO was founded in 2020 with more than $800 million in capital. While the company initially emerged with a focus on the U.S. and Canada, by 2023 it had announced plans to build factories in the Saudi Arabia and the United Arab Emirates.
“As a highly experienced team already supporting a leading pharmaceutical company with their GLP-1 products, this expansion further supports Resilience’s mission to ensure adequate biomanufacturing capacity by addressing and overcoming historic manufacturing challenges throughout the industry,” said Rahul Singhvi, Resilience’s chief executive officer.
 Overview of outsourcing trends 
